Interleukin-33 alleviates the immunosuppressive tumor microenvironment and enhances anti-programmed death ligand-1 immunotherapy efficacy in hepatocellular carcinoma
Open Access
- 22 September 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 139 (21) , 3295-3307
Abstract
Background: Hepatocellular carcinoma (HCC) is one of the most lethal malignancies worldwide. The immunosuppressive tumor microenvironment (TME) and limited response to immune checkpoint blockade (ICB) therapy remain major obstacles to improving HCC prognosis. Interleukin-33 (IL-33) is a multifunctional cytokine that plays critical roles in cancer development; however, its function in HCC remains unclear. Methods: Cell proliferation was evaluated using colony formation and 5-ethynyl-2′-deoxyuridine (EdU) staining assays. Tumor-bearing models were established in both immunocompetent and immunodeficient mice. Multiplex immunofluorescence and flow cytometry were performed to assess TME characteristics. RNA sequencing and Western blot analyses were conducted to investigate the underlying mechanisms. Results: We found that IL-33 downregulation was significantly associated with shorter survival in patients with HCC. IL-33 treatment markedly inhibited tumor progression, whereas endogenous IL-33 blockade accelerated tumor growth in immunocompetent mice. However, IL-33 showed no significant effect on cell proliferation in vitro and failed to suppress tumor growth in immunodeficient mice lacking T cells. IL-33 administration notably reduced immunosuppressive tumor-associated macrophages and myeloid-derived suppressor cells, while substantially increasing CD8 + T cells, particularly functional interferon (IFN)-γ + CD8 + T cells, within the TME. Mechanistically, IL-33 activated the stimulator of interferon genes/interferon regulatory factor signaling axis, enhanced IFN-γ secretion, and inhibited Rictor and programmed death 1 expression in mouse tumors. Furthermore, HCC specimens with high IL-33 expression exhibited more tertiary lymphoid structures. In addition, combined IL-33 and anti-programmed death ligand-1 therapy synergistically reduced tumor burden and further enhanced antitumor immunity in vivo . Conclusion: These findings indicate that IL-33 alleviates immunosuppression and enhances ICB efficacy, providing novel insights into its role in HCC immunotherapy.Keywords
This publication has 40 references indexed in Scilit:
- Lymph node macrophages drive immune tolerance and resistance to cancer therapy by induction of the immune-regulatory cytokine IL-33Cancer Cell, 2025
- A Noninvasive Approach to Evaluate Tumor Immune Microenvironment and Predict Outcomes in Hepatocellular CarcinomaPhenomics, 2023
- Immune checkpoint inhibitor resistance in hepatocellular carcinomaCancer Letters, 2022
- Disrupted BRCA1‐PALB2 interaction induces tumor immunosuppression and T‐lymphocyte infiltration in HCC through cGAS‐STING pathwayHepatology, 2022
- An RNA–RNA crosstalk network involving HMGB1 and RICTOR facilitates hepatocellular carcinoma tumorigenesis by promoting glutamine metabolism and impedes immunotherapy by PD-L1+ exosomes activitySignal Transduction and Targeted Therapy, 2021
- Structures and Mechanisms in the cGAS-STING Innate Immunity PathwayImmunity, 2020
- The reciprocal interaction between tumor cells and activated fibroblasts mediated by TNF-α/IL-33/ST2L signaling promotes gastric cancer metastasisOncogene, 2019
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trialThe Lancet Oncology, 2018
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trialThe Lancet, 2017
- Tumor‐infiltrating, interleukin‐33–producing effector‐memory CD8+ T cells in resected hepatocellular carcinoma prolong patient survivalHepatology, 2015